Inhibitex

About:

Inhibitex is a clinical-stage biopharmaceutical company that develops treatments for bacterial and viral infections.

Top Investors: OrbiMed, New Enterprise Associates, Great Point Partners, William Blair, QVT Financial

Description:

Inhibitex develops antibody based products to prevent and treat bacterial and fungal infections. The company is focused on the development of small molecule antiviral compounds, and in particular, therapies to treat shingles and chronic hepatitis C infections.

Total Funding Amount:

$122M

Headquarters Location:

Alpharetta, Georgia, United States

Founded Date:

1994-01-01

Founders:

Joseph Patti

Number of Employees:

11-50

Last Funding Date:

2009-10-28

IPO Status:

Delisted

Industries: